To note

**Evaluating the impact of revalidation**

**Issue**

1. We have appointed a consortium led by the University of Plymouth to undertake an evaluation of the impact of revalidation over the next three years.

**Recommendation**

2. The Strategy and Policy Board is asked to note the appointment of a consortium led by the University of Plymouth to undertake an evaluation of the impact of revalidation.
Evaluating the impact of revalidation

Issue

3 In April 2014, we went out to tender for a third party supplier to undertake an evaluation of revalidation, based on the Revalidation Evaluation Framework developed in 2013. The tender campaign was very successful with over 70 application forms requested and 20 individuals attending a supplier day, held in London on 15 May 2014.

4 Public and patient involvement (PPI) is one of the main pillars of the evaluation framework. As part of the selection process we invited the patient representative from the Revalidation Implementation Advisory Board, Sol Mead, to sit on the selection panel as an observer. Other members of the Panel included David Darton (Head of Intelligence and Insight), Philip Finn (Head of Regulatory Development and Evaluation), Ben Whur (Assistant Director, Registration and Revalidation), Gordon Duffus (Head of Procurement) and Clare Barton (Assistant Director, Registration and Revalidation).

5 A consortium led by the University of Plymouth attained the highest overall score and on that basis we have appointed them to undertake the evaluation. The ten-day contractual cooling-off period concludes on 26 July 2014.

6 The Department of Health (England) is in the process of commissioning a related piece of work looking into the benefits and tracking the impact of revalidation. Its scope is limited to England and focuses on the impact of revalidation on organisations rather than individual practitioners. They are due to appoint a supplier in September. We are meeting with the Department regularly to discuss the two pieces of work and we sat as observers on their selection panel which met in June 2014.

7 The project team will begin work with the University of Plymouth shortly to develop a detailed plan for the evaluation, based on their successful proposal, and we expect a first interim report at the end of the first quarter of 2015.
Supporting information

How this issue relates to the corporate strategy and business plan

8 The evaluation of revalidation supports strategic aim 2 which is to ‘Help to raise standards of medical education and practice’. It is specifically mentioned in our Business Plan, ‘Delivering an evaluation framework to determine the extent to which revalidation is delivering a real improvement in practice standards and patient safety’.

What equality and diversity considerations relate to this issue

9 As highlighted in the Revalidation Evaluation Framework, the evaluation will need to explore whether there are any differential impacts on doctors from across the protected characteristics, working in different environments and at different stages of their career.

If you have any questions about this paper please contact: Philip Finn, Head of Regulatory Development and Evaluation, pfinn@gmc-uk.org, 020 7189 5423.